Testing ivonescimab in people whose glioblastoma has come back
Official title: A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a drug called ivonescimab in people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has returned.
Read our full plain-language summary
What the trial team says
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Key facts
- Registry number
- NCT06672575
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Glioblastoma
Where it is running
This trial lists 2 sites.
-
Texas
- The University of Texas M. D. Anderson Cancer Center (Houston)
- The University of Texas MD Anderson Cancer Center (Houston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.